Study of rmhTNF for stomach and colon cancer with spread in the belly
Part of Cancer, Digestive system clinical trials.
This study tests a drug called rmhTNF given directly into the belly to prevent or treat cancer spread (peritoneal metastasis) and fluid buildup (malignant ascites) in people with advanced stomach or colorectal cancer. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced stomach or colorectal cancer that has spread or come back.
- You are between 18 and 80 years old.
- You are not pregnant or breastfeeding, and if male, you agree to use birth control.
- Your blood counts and liver/kidney function are within certain limits (your doctor can check this).
- You are generally able to care for yourself (ECOG score 0-1).
- You are not allergic to TNF, biological drugs, or penicillin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of low-dose radiation, chemotherapy, and an immunotherapy drug (AK112) for people with advanced stomach or gastroesophageal junction cancer that has progressed after first-line treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
This trial tests a combination of a modified TNF drug (rmhTNF-NC), an immunotherapy (tislelizumab), and radiation therapy for people with digestive system cancers that have caused moderate or large amounts of fluid buildup in the belly (ascites) and when standard treatments have stopped working. The goal is to see if this approach can help control the ascites and improve symptoms.
This trial tests a new type of immune cell therapy called RAK cells for people with late-stage stomach cancer that has spread and stopped responding to standard treatments. The goal is to see if it is safe and helps control the cancer.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.